Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

President, Head of R&D

Sr. Advisor & Strategy Officer

Chief Financial Officer

COO and General Counsel

Chief Executive Officer

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of oncology, non-alcoholic steatohepatitis (NASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in clinical development for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy cand...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-03	Premium	sold	Premium	Premium	Premium	-
2024-04-03	Premium	sold	Premium	Premium	Premium	-
2024-04-03	Premium	sold	Premium	Premium	Premium	-
2024-04-02	Premium	sold	Premium	Premium	Premium	-
2024-04-02	Premium	sold	Premium	Premium	Premium	-
2024-04-02	Premium	sold	Premium	Premium	Premium	-
2024-04-01	Premium	sold	Premium	Premium	Premium	-
2024-04-01	Premium	sold	Premium	Premium	Premium	-
2024-04-01	Premium	sold	Premium	Premium	Premium	-
2024-01-23	Premium	acquired	Premium	Premium	Premium	President, Head of R&D
2024-01-23	Premium	acquired	Premium	Premium	Premium	Sr. Advisor & Strategy Officer
2024-01-23	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-01-23	Premium	acquired	Premium	Premium	Premium	COO and General Counsel
2023-11-30	Premium	bought	Premium	Premium	Premium	Chief Financial Officer
2023-11-30	Premium	bought	Premium	Premium	Premium	COO and General Counsel
2023-11-15	Premium	acquired	Premium	Premium	Premium	Sr. Advisor & Strategy Officer
2023-05-31	Premium	bought	Premium	Premium	Premium	Chief Financial Officer
2023-05-31	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2023-05-31	Premium	bought	Premium	Premium	Premium	COO and General Counsel
2022-12-23	Premium	bought	Premium	Premium	Premium	-
2022-12-23	Premium	bought	Premium	Premium	Premium	-
2022-12-23	Premium	bought	Premium	Premium	Premium	-
2022-12-23	Premium	bought	Premium	Premium	Premium	-
2022-11-30	Premium	bought	Premium	Premium	Premium	Chief Financial Officer
2022-11-30	Premium	bought	Premium	Premium	Premium	Chief Executive Officer

TERN - Terns Pharmaceuticals, Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for TERN